Regulatory Strategy · Clinical Development · Medical Affairs
Twenty-plus years of in-house pharmaceutical leadership applied to regulatory strategy, clinical development, and medical affairs, with compliance, commercial analytics, and market research support when your program calls for it.
About
Pellucid Advantage was founded more than a decade ago by Eric R. Kinzler, PhD, who leads the firm today as its principal consultant. Eric holds a doctorate in Cellular and Molecular Biology from UW–Madison and brings more than two decades of in-house leadership and consulting across branded, generic, and investigational products.
Eric has served as Vice President of Medical & Regulatory Affairs, Head of Quality, Study Director at GLP/CLIA/CAP-accredited laboratories, and scientific lead at FDA Advisory Committee meetings — including providing expert testimony. He has helped drive numerous drug approvals and end-to-end product launches, contributing to several approved applications, class-wide REMS programs, and quality management systems built from the ground up.
Healthcare compliance is a discipline of its own, and one Eric has worked in for many years. He served as an Independent Board Member overseeing a company's obligations under an OIG Corporate Integrity Agreement, and today is a key member of the compliance committee for a commercial-stage specialty pharmaceutical company, contributing across its compliance program: policies and SOPs, training, promotional and field-force oversight, HCP interactions and transparency reporting, monitoring and auditing, and the review of concerns as they arise.
Today that experience extends into the commercial organization. Eric built and runs a sales analytics and reporting platform and a prescriber market research program for specialty pharmaceutical clients, giving field teams and executives timely, decision-ready insight, built by someone who knows exactly what the data can and cannot be used for.
Services
Three practices, one point of accountability. Most clients start with one and find the others close at hand.
Executive-level expertise on demand for branded and generic manufacturers, from your first Agency meeting through launch, post-marketing commitments, and the day-to-day compliance of a commercial organization.
Pre-IND through NDA/ANDA strategy, FDA meeting preparation and facilitation, Advisory Committee support including expert testimony, clinical data analysis and interpretation, and regulatory document development.
Regulatory strategy and FDA communications for generic manufacturers: controlled correspondence, responses to deficiency letters and information requests, labeling and shared-system REMS questions, and post-approval changes.
End-to-end launch readiness: go-to-market strategy, medical affairs build-out, payer value proposition development, access and reimbursement planning, Scientific Advisory Boards, publication strategy, and promotional material review.
Advertising and promotion strategy, medical-legal-regulatory (MLR) review committee design and facilitation, REMS program management, FDA 483 response, CAPA implementation, and post-marketing commitment oversight.
Building and supporting compliance programs aligned with OIG guidance: compliance officer and committee structure, policies and SOPs, training, field-force and promotional oversight, Anti-Kickback and fair-market-value review, Open Payments and state transparency reporting, PhRMA Code alignment, auditing and monitoring, and investigations — including ongoing compliance committee support.
Design, implementation, and management of QMS aligned with cGMP requirements. Policy and SOP development, compliance training programs, and audit readiness — including FDA and pharmacovigilance inspection support.
Medical information and pharmacovigilance operations, MSL program design, Advisory Board execution, KOL development, scientific communications, and cross-functional support for field teams and strategic partners.
Due diligence support, co-promote structuring, product divestitures, and transfers to new ownership — including supply chain transition, REMS transfers, and regulatory notifications required at change of ownership.
Study protocol design, laboratory oversight, data analysis and interpretation, and regulatory submissions for abuse-deterrent formulations — including Category 1–4 testing reports aligned with FDA guidance.
Sales and prescribing analytics for your field team and leadership, delivered as a managed service. We take in your prescription, call-activity, payer, and territory data and deliver finished, decision-ready reports every week, with compliance rules built in.
Weekly territory and representative reports delivered through secure links built for phones and tablets: trends, top prescribers, call coverage, and opportunity, refreshed automatically when new data lands.
Weekly executive summaries and slide-ready decks with written commentary, quarter-to-date pacing against goals, payer and pharmacy dynamics, and the exceptions that need attention.
Plan design support and back-testing, then period-by-period calculation and publishing of results, reconciled to the same data the field sees every week.
Prescriber segmentation, target and call-plan lists, growth and decline monitoring, and payer-mix grading, with PDRP opt-outs and other restrictions applied automatically.
A secure, client-specific AI assistant that answers plain-English questions about your own data, plus practical AI consulting for regulated organizations: workflow automation, document review, and responsible deployment.
Intake and validation of syndicated prescription, specialty pharmacy, co-pay, and CRM feeds; vendor restatement handling; territory alignment; and quality checks, so the numbers hold up.
Prescriber and stakeholder research designed to stand up to compliance review, from the first contact to the final payment.
Research objectives, discussion guides, and one-on-one interviews conducted by a senior pharmaceutical professional, with findings reported in aggregate.
Selection criteria documented before any contact, invitations respondents choose to answer themselves, secure self-scheduling, and a complete audit trail. Field teams never learn who took part.
Fair-market-value honoraria by credential, written consulting agreements, and support for Open Payments (Sunshine Act) reporting.
How We Work
Every engagement is led personally by Eric, from scoping and strategy through the final work product. Clients get senior judgment from the first call, not a hand-off to junior staff.
When a program needs more hands or specialized depth, Eric brings in trusted colleagues he has worked with for years — regulatory writers and counsel, biostatisticians, pharmacovigilance and medical information professionals, quality and compliance specialists, and data engineers — and manages them as one team under a single engagement.
Eric owns the strategy and signs off on every deliverable.
Specialists join when the program calls for them, and only then.
One contract, one contact, one standard of quality.
Track Record
Get in Touch
Whether you're preparing for a regulatory milestone, building out medical affairs, strengthening your compliance program, standing up commercial reporting for a launch, or planning prescriber research — we'd welcome an introductory conversation.
Engagements are structured to fit your needs: project-based, retainer, managed service, or fractional executive support. Confidential. No long-term commitments required to get started.
And if we aren't the right fit for your challenge, we'll tell you so and point you toward someone who is.
✉ info@pellucidadvantage.com